Haemonetics share price today

(HAE)

Haemonetics share price is $83.34 & -₹83.34 as on 12 Dec 2024, 2.30 'hrs' IST

$83.34

▲

-0.54

(-0.64%)

Market is closed - opens 8 PM, 12 Dec 2024

View live Haemonetics share price in Dollar and Rupees. Guide to invest in Haemonetics from India. Also see the sentimental analysis on Indian investors investing in Haemonetics. Get details on the Indian mutual funds that are investing in Haemonetics. Get Analyst recommendations and forecasts along with all the Haemonetics's financials.

Haemonetics share price movements

$82.85
$84.44
$83.34
0.59%
Downside
Day's Volatility :1.88%
Upside
1.3%
$70.25
$97.97
$83.34
15.71%
Downside
52 Weeks Volatility :28.29%
Upside
14.93%

Haemonetics Returns

Period	Haemonetics Corp	Sector (Health Care)	Index (Russel 2000)
3 Months	13.76%	-8.8%	0.0%
6 Months	-3.15%	-2.7%	0.0%
1 Year	-5.28%	6.5%	0.0%
3 Years	60.95%	5.6%	-20.0%

Haemonetics Key Statistics

in dollars & INR

Previous Close	$83.88
Open	$84.44
Today's High	$84.44
Today's Low	$82.85
Market Capitalization	$4.2B
Today's Volume	$720.3K
52 Week High	$97.97
52 Week Low	$70.25
Revenue TTM	$1.4B
EBITDA	$314.2M
Earnings Per Share (EPS)	$2.41
PE Ratio	34.81
Profit Margin	9.1%
Quarterly Earnings Growth YOY	0.38%
Return On Equity TTM	13.97%

How to invest in Haemonetics from India?

It is very easy for Indian residents to invest directly in Haemonetics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Haemonetics stock in both rupees (INR) and dollars (USD). Search for Haemonetics or HAE on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Haemonetics or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Haemonetics shares which would translate to -0.000 fractional shares of Haemonetics as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Haemonetics

Period: Sep 12, 2024 to Dec 11, 2024. Change in 30 Days versus previous period

Search volume for Haemonetics on INDmoney from India has grown in the last 30 days as on Dec 12, 2024. 0% more investors are searching Haemonetics in the last 30 days versus the previous period.

Global Institutional Holdings in Haemonetics

BlackRock Inc
11.87%
Vanguard Group Inc
10.29%
Capital Research Global Investors
8.85%
Wellington Management Company LLP
8.37%
Neuberger Berman Group LLC
8.02%
T. Rowe Price Investment Management,Inc.
5.68%

Analyst Recommendation on Haemonetics

Buy

72%Buy

27%Hold

0%Sell

Based on 11 Wall street analysts offering stock ratings for Haemonetics(by analysts ranked 0 to 5 stars)

Based on 11 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Haemonetics

What analysts predicted

Upside of 33.52%

Current:

$83.34

Target:

$111.27

Insights on Haemonetics

Price Movement
In the last 1 month, HAE stock has moved down by -10.8%
Increasing Revenue
Revenue is up for the last 2 quarters, 336.17M → 345.51M (in $), with an average increase of 2.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 38.37M → 33.83M (in $), with an average decrease of 11.8% per quarter
HAE vs ISRG (1 yr)
In the last 1 year, Intuitive Surgical, Inc. has given 69.5% return, outperforming this stock by 73.1%
Price to Sales
ForHAE every $1 of sales, investors are willing to pay $3.1, whereas for Intuitive Surgical, Inc., the investors are paying $24.5 for every $1 of sales.

Haemonetics Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$967.6M	↑ 7.04%
Net Income	$55.0M	↑ 20.73%
Net Profit Margin	5.69%	↑ 0.65%

	FY20	Y/Y Change
Revenue	$988.5M	↑ 2.16%
Net Income	$76.5M	↑ 39.09%
Net Profit Margin	7.74%	↑ 2.05%

	FY21	Y/Y Change
Revenue	$870.5M	↓ 11.94%
Net Income	$79.5M	↑ 3.85%
Net Profit Margin	9.13%	↑ 1.39%

	FY22	Y/Y Change
Revenue	$993.2M	↑ 14.1%
Net Income	$43.4M	↓ 45.42%
Net Profit Margin	4.37%	↓ 4.76%

	FY23	Y/Y Change
Revenue	$1.2B	↑ 17.67%
Net Income	$115.4M	↑ 166.05%
Net Profit Margin	9.87%	↑ 5.5%

	FY24	Y/Y Change
Revenue	$1.3B	↑ 12.01%
Net Income	$117.6M	↑ 1.87%
Net Profit Margin	8.98%	↓ 0.89%

	Q2 FY23	Q/Q Change
Revenue	$311.3M	↑ 2.27%
Net Income	$41.0M	↑ 39.68%
Net Profit Margin	13.18%	↑ 3.53%

	Q3 FY23	Q/Q Change
Revenue	$318.2M	↑ 2.2%
Net Income	$24.9M	↓ 39.31%
Net Profit Margin	7.83%	↓ 5.35%

	Q4 FY23	Q/Q Change
Revenue	$336.3M	↑ 5.68%
Net Income	$31.2M	↑ 25.43%
Net Profit Margin	9.29%	↑ 1.46%

	Q1 FY24	Q/Q Change
Revenue	$343.3M	↑ 2.09%
Net Income	$20.4M	↓ 34.81%
Net Profit Margin	5.93%	↓ 3.36%

	Q2 FY24	Q/Q Change
Revenue	$336.2M	↓ 2.07%
Net Income	$38.4M	↑ 88.41%
Net Profit Margin	11.41%	↑ 5.48%

	Q3 FY24	Q/Q Change
Revenue	$345.5M	↑ 2.78%
Net Income	$33.8M	↓ 11.84%
Net Profit Margin	9.79%	↓ 1.62%

	FY19	Y/Y Change
Total Assets	$1.3B	↑ 3.02%
Total Liabilities	$606.9M	↑ 25.16%

	FY20	Y/Y Change
Total Assets	$1.3B	↓ 0.6%
Total Liabilities	$680.0M	↑ 12.05%

	FY21	Y/Y Change
Total Assets	$1.8B	↑ 43.63%
Total Liabilities	$1.1B	↑ 60.04%

	FY22	Y/Y Change
Total Assets	$1.9B	↑ 2.19%
Total Liabilities	$1.1B	↑ 2.03%

	FY23	Y/Y Change
Total Assets	$1.9B	↑ 4.04%
Total Liabilities	$1.1B	↑ 0.59%

	FY24	Y/Y Change
Total Assets	$2.2B	↑ 13.48%
Total Liabilities	$1.2B	↑ 10.64%

	Q2 FY23	Q/Q Change
Total Assets	$2.0B	↑ 1.42%
Total Liabilities	$1.1B	↓ 1.72%

	Q3 FY23	Q/Q Change
Total Assets	$2.0B	↑ 2.5%
Total Liabilities	$1.1B	↑ 1.82%

	Q4 FY23	Q/Q Change
Total Assets	$2.2B	↑ 9.4%
Total Liabilities	$1.3B	↑ 12.48%

	Q1 FY24	Q/Q Change
Total Assets	$2.2B	↓ 0.22%
Total Liabilities	$1.2B	↓ 1.71%

	Q2 FY24	Q/Q Change
Total Assets	$2.5B	↑ 15.73%
Total Liabilities	$1.6B	↑ 32.37%

	Q3 FY24	Q/Q Change
Total Assets	$2.5B	↓ 0.62%
Total Liabilities	$1.6B	↑ 0.66%

	FY19	Y/Y Change
Operating Cash Flow	$159.3M	↓ 27.71%
Investing Cash Flow	$-116.1M	↑ 84.24%
Financing Cash Flow	$-50.6M	↓ 58.03%

	FY20	Y/Y Change
Operating Cash Flow	$158.2M	↓ 0.67%
Investing Cash Flow	$-57.2M	↓ 50.77%
Financing Cash Flow	$-131.2M	↑ 159.16%

	FY21	Y/Y Change
Operating Cash Flow	$108.8M	↓ 31.23%
Investing Cash Flow	$-425.4M	↑ 644.09%
Financing Cash Flow	$367.5M	↓ 380.05%

	FY22	Y/Y Change
Operating Cash Flow	$172.3M	↑ 58.32%
Investing Cash Flow	$-86.3M	↓ 79.7%
Financing Cash Flow	$-15.7M	↓ 104.29%

	FY23	Y/Y Change
Operating Cash Flow	$273.1M	↑ 58.51%
Investing Cash Flow	$-143.8M	↑ 66.53%
Financing Cash Flow	$-100.4M	↑ 537.27%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$19.1M	↓ 76.03%
Investing Cash Flow	$-15.3M	↓ 15.24%
Financing Cash Flow	$-598.0K	↓ 62.69%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$99.1M	↑ 419.35%
Investing Cash Flow	$-25.1M	↑ 64.7%
Financing Cash Flow	$-7.2M	↑ 1099.33%

Haemonetics Technicals Summary

Sell

Neutral

Buy

Haemonetics is currently in a neutral trading position according to technical analysis indicators.

Haemonetics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Haemonetics Corp	-10.75%	-3.15%	-5.28%	60.95%	-29.36%
Intuitive Surgical, Inc.	1.22%	28.54%	65.25%	59.71%	176.39%
Resmed Inc.	-0.58%	15.73%	42.81%	-6.72%	57.55%
Becton, Dickinson And Company	-4.42%	-4.71%	-8.08%	-12.57%	-18.1%
West Pharmaceutical Services Inc	-2.89%	-5.37%	-11.53%	-27.83%	116.11%
Alcon Ag	-0.37%	-5.23%	15.35%	3.59%	53.9%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Haemonetics Corp	34.81	34.81	1.34	3.96	0.14	0.06	NA	17.44
Intuitive Surgical, Inc.	87.76	87.76	4.06	6.84	0.16	0.08	NA	43.75
Resmed Inc.	32.57	32.57	1.86	7.71	0.24	0.13	0.01	35.39
Becton, Dickinson And Company	37.72	37.72	1.02	13.11	0.06	0.03	0.02	89.47
West Pharmaceutical Services Inc	47.14	47.14	5.94	6.66	0.18	0.1	0.0	37.96
Alcon Ag	36.67	36.67	3.1	3.03	0.06	0.03	0.0	43.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Haemonetics Corp	Buy	$4.2B	-29.36%	34.81	9.1%
Intuitive Surgical, Inc.	Buy	$195.9B	176.39%	87.76	28.51%
Resmed Inc.	Buy	$36.0B	57.55%	32.57	23.15%
Becton, Dickinson And Company	Buy	$64.0B	-18.1%	37.72	7.13%
West Pharmaceutical Services Inc	Buy	$23.0B	116.11%	47.14	17.37%
Alcon Ag	Buy	$42.7B	53.9%	36.67	11.89%

About Haemonetics

haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right

Organization	Haemonetics
Employees	3657
CEO	Mr. Christopher A. Simon
Industry	Health Technology

Management People of Haemonetics

Name	Title
Mr. Christopher A. Simon	CEO, President & Director
Mr. James C. D'Arecca CPA	CFO, Executive VP & Financial Officer
Ms. Michelle L. Basil J.D.	Executive VP, General Counsel & Secretary
Mr. Josep Lluis Llorens	Executive Vice President of Global Manufacturing & Supply Chain
Ms. Farris Maryanne Maunsell	VP, Chief Accounting Officer & Principal Accounting Officer
Ms. Olga Guyette	Senior Director of Investor Relations
Mr. Rajeev Varma	Senior Vice President of Strategy & Corporate Development
Ms. Laurie A. Miller	Senior VP & Chief Human Resources Officer
Dr. Jan Hartmann M.D.	Senior VP & Chief Medical Officer
Mr. Stewart W. Strong	President of Global Hospital

Important FAQs about investing in Haemonetics from India :

What is Haemonetics share price today?

Haemonetics (HAE) share price today is $83.34.

Can Indians buy Haemonetics shares?

Yes, Indians can invest in the Haemonetics (HAE) from India.

With INDmoney, you can buy Haemonetics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Haemonetics at zero transaction cost.

How can I buy Haemonetics shares from India?

It is very easy to buy Haemonetics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Haemonetics be purchased?

Yes, you can buy fractional shares of Haemonetics with INDmoney app.

What are the documents required to start investing in Haemonetics stocks?

To start investing in Haemonetics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.